BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 12388489)

  • 1. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
    Bredella MA; Caputo GR; Steinbach LS
    AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET.
    van Laarhoven HW; de Geus-Oei LF; Wiering B; Lok J; Rijpkema M; Kaanders JH; Krabbe PF; Ruers T; Punt CJ; van der Kogel AJ; Oyen WJ; Heerschap A
    Radiology; 2005 Oct; 237(1):181-8. PubMed ID: 16183932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
    Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
    Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
    Comoretto M; Balestreri L; Borsatti E; Cimitan M; Franchin G; Lise M
    Radiology; 2008 Oct; 249(1):203-11. PubMed ID: 18710963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
    Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
    Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium.
    Roivainen A; Parkkola R; Yli-Kerttula T; Lehikoinen P; Viljanen T; Möttönen T; Nuutila P; Minn H
    Arthritis Rheum; 2003 Nov; 48(11):3077-84. PubMed ID: 14613269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging.
    Yen RF; Hung RL; Pan MH; Wang YH; Huang KM; Lui LT; Kao CH
    Cancer; 2003 Jul; 98(2):283-7. PubMed ID: 12872346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery.
    van der Woude HJ; Bloem JL; Verstraete KL; Taminiau AH; Nooy MA; Hogendoorn PC
    AJR Am J Roentgenol; 1995 Sep; 165(3):593-8. PubMed ID: 7645476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
    Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
    Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of soft-tissue sarcoma recurrence: added value of functional MR imaging techniques at 3.0 T.
    Del Grande F; Subhawong T; Weber K; Aro M; Mugera C; Fayad LM
    Radiology; 2014 May; 271(2):499-511. PubMed ID: 24495264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
    Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K
    Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
    Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
    Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
    Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy.
    van Rijswijk CS; Geirnaerdt MJ; Hogendoorn PC; Taminiau AH; van Coevorden F; Zwinderman AH; Pope TL; Bloem JL
    Radiology; 2004 Nov; 233(2):493-502. PubMed ID: 15459325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric Assessment of Treatment Response in High-Grade Soft-Tissue Sarcomas with Anatomic and Functional MR Imaging Sequences.
    Soldatos T; Ahlawat S; Montgomery E; Chalian M; Jacobs MA; Fayad LM
    Radiology; 2016 Mar; 278(3):831-40. PubMed ID: 26390048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.